Status:
COMPLETED
Exercise and Galactooligosaccharide Supplementation on Inflammation and Iron Absorption (FexerGOS)
Lead Sponsor:
North-West University, South Africa
Collaborating Sponsors:
Swiss Federal Institute of Technology
King's College London
Conditions:
Resistance Exercise
Eligibility:
FEMALE
18-35 years
Phase:
NA
Brief Summary
Iron depletion is common in female athletes depending on the sports discipline. Endurance and resistance exercise can induce inflammation thereby reducing dietary iron absorption. Galacto-oligosacchar...
Detailed Description
Iron depletion is common in athletes, particularly in females, reaching prevalence rates up to 70% depending on the sports discipline. As iron is essential for energy production and oxygen transport, ...
Eligibility Criteria
Inclusion
- Female athlete.
- Train at least 6 hours per week at moderate to high intensity.
- Having low to moderate iron stores.
- Willingness to consume the study supplement GOS during the intervention period.
- Willingness not to consume daily nutritional supplements containing \>20 mg iron and/or pre- or probiotics (excluding food and beverages containing live cultures such as yoghurt, raw milk and cheese) during the study.
- Willingness to not take any iron-containing supplements two days before and during the iron absorption study days or vitamin C on the iron absorption study days.
Exclusion
- Haemoglobin \<11 g/dl.
- Treated or self-reported chronic disease, malabsorptive or gastrointestinal disorders (e.g. irritable bowel syndrome, functional bloating).
- Pregnancy or lactation.
- Subjects who cannot be expected to comply with the study protocol.
- Difficulty drawing blood due to poor quality veins.
- Individuals that have a fear of needles or suffer from vaso-vagal episodes when exposed to blood.
- Participants who plan to start or stop the use of contraceptives before or during study period.
- Participants who are lactose intolerant.
- Participants who donated blood in the past 4 months or plan to donate during the study period.
- Participants who use chronic anti-inflammatory medication such as corticosteroids or non-steroidal anti-inflammatory medication (NSAIDS).
Key Trial Info
Start Date :
March 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 25 2024
Estimated Enrollment :
22 Patients enrolled
Trial Details
Trial ID
NCT06038656
Start Date
March 1 2024
End Date
November 25 2024
Last Update
March 13 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Este Vorster Research Facility
Potchefstroom, North West, South Africa, 2531